National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$33.00
add to cart

Rights & Permissions

topleft topright

Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda (1993)
Institute of Medicine (IOM)

Citation Manager

. "B7. Comments on Session II." Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda. Washington, DC: The National Academies Press, 1993.

Please select a format:

BibTeX EndNote RefMan


Page
188
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
SUMMARY

In summary, I would leave you with six points. First, with regard to the safety issue, I think that issue has largely been resolved. Second, I think we all concur that better dose-finding studies are needed. Third, we need a way to come up with a less cumbersome regimen for administering RU 486, particularly in conjunction with a prostaglandin analogue. Fourth, I think a great potential use for RU 486 and similar drugs is to augment second-trimester abortions. Fifth, another very exciting potential is use as a post-coital contraceptive. Sixth, and finally, we need much more work, such as we have heard this morning, with these other scores of compounds.

Page
188